Research Article
Cryptococcosis in Patients following Kidney Transplantation: A 9-Year Retrospective Clinical Analysis at a Chinese Tertiary Hospital
Table 1
Demographic and clinical data of KT recipients with cryptococcosis (n = 37).
| | Variable | N (%) |
| | Male sex | 23 (62.3%) |
| | Age at diagnosis (years) | 49.5 ± 9.38 |
| | Underlying diseases | | | Hypertension | 15 (40.5%) | | Chronic viral hepatitis B | 10 (27.0%) | | Type 2 diabetes | 5 (13.5%) | | Chronic viral hepatitis C | 3 (8.1%) | | Systemic lupus erythematosus | 1 (2.7%) |
| | Immunosuppressive regimen | | | Prednisone | 37 (100%) | | Mycophenolate mofetil | 30 (80.1%) | | Mycophenolic acid | 1 (2.7%) | | Tacrolimus | 29 (78.4%) | | Cyclosporine A | 8 (21.6%) | | Azathioprine | 2 (5.4%) | | Leflunomide | 2 (5.4%) | | Rapamycin | 2 (5.4%) |
| | Posttransplantation time to diagnosis of cryptococcosis (years) | 7.0 ± 5.50 | | <2 year | 7 (18.9%) | | >2 years | 30 (81.1%) |
| | Organ involvement | | | Central nervous system | 26 (70.3%) | | Lungs | 18 (48.6%) | | Skin | 2 (5.4%) |
| | Disseminated cryptococcosis | 17 (45.9%) |
| | Cryptococcemia | 10 (27.0%) |
| | Baseline creatinine level (μmol·L−1) | 202.90 ± 153.40 |
|
|
